454 related articles for article (PubMed ID: 10418180)
21. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.
Morfini M; Longo G; Messori A; Lee M; White G; Mannucci P
Thromb Haemost; 1992 Oct; 68(4):433-5. PubMed ID: 1448776
[TBL] [Abstract][Full Text] [Related]
22. [Recombinant factor VIII concentrate].
Fukutake K
Rinsho Byori; 1992 Mar; Suppl 92():94-106. PubMed ID: 1583781
[No Abstract] [Full Text] [Related]
23. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
Ewenstein BM; Collins P; Tarantino MD; Negrier C; Blanchette V; Shapiro AD; Baker D; Spotts G; Sensel M; Yi SE; Gomperts ED
Semin Hematol; 2004 Jan; 41(1 Suppl 2):1-16; discussion 16-8. PubMed ID: 15071785
[TBL] [Abstract][Full Text] [Related]
24. Two years' experience with two recombinant factor VIII concentrates.
Brackmann HH; Aygören E; Scharrer I; Schwaab R; Hammerstein U; Oldenburg J
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):421-4. PubMed ID: 8329567
[TBL] [Abstract][Full Text] [Related]
25. [Percutaneous nephrolithotripsy supported by recombinant factor VIII in a patient with hemophilia A, a Jehovah's Witness].
Azuno Y; Kaku K
Rinsho Ketsueki; 1995 Dec; 36(12):1337-41. PubMed ID: 8587168
[TBL] [Abstract][Full Text] [Related]
26. Hemophilia--an ancient disease with new problems and new solutions.
Rogers JS; Ritchey AK
W V Med J; 1992 Feb; 88(2):50-3. PubMed ID: 1557907
[TBL] [Abstract][Full Text] [Related]
27. Anaphylaxis after treatment with recombinant factor VIII.
Shopnick RI; Kazemi M; Brettler DB; Buckwalter C; Yang L; Bray G; Gomperts ED
Transfusion; 1996 Apr; 36(4):358-61. PubMed ID: 8623140
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
Nemes L; Lissitchkov T; Dobaczewski G; Klukowska A; Komrska V; Zimmermann R; Auerswald G; Engl W; Abbühl B; Pavlova BG; Ehrlich HJ
Acta Haematol; 2008; 119(2):89-97. PubMed ID: 18305381
[TBL] [Abstract][Full Text] [Related]
29. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.
Schimpf K; Brackmann HH; Kreuz W; Kraus B; Haschke F; Schramm W; Moesseler J; Auerswald G; Sutor AH; Koehler K
N Engl J Med; 1989 Oct; 321(17):1148-52. PubMed ID: 2507917
[TBL] [Abstract][Full Text] [Related]
30. Developing rDNA products for treatment of hemophilia A.
Kaufman RJ
Trends Biotechnol; 1991 Oct; 9(10):353-9. PubMed ID: 1367761
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs.
Smid WM; van der Meer J; Halie MR
Haemostasis; 1995; 25(5):229-36. PubMed ID: 7489961
[TBL] [Abstract][Full Text] [Related]
32. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
Goldsmith JC
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
[TBL] [Abstract][Full Text] [Related]
33. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
34. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
35. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.
Franchini M
Blood Transfus; 2010 Oct; 8(4):292-6. PubMed ID: 20967172
[No Abstract] [Full Text] [Related]
36. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
37. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.
Mannucci PM
Blood Transfus; 2010 Oct; 8(4):288-91. PubMed ID: 20967171
[No Abstract] [Full Text] [Related]
38. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
[TBL] [Abstract][Full Text] [Related]
39. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated for two years with a monoclonal purified factor VIII concentrate.
Smid WM; van der Meer J; Smit JW; Halie MR
Thromb Haemost; 1993 Apr; 69(4):306-10. PubMed ID: 8388579
[TBL] [Abstract][Full Text] [Related]
40. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation.
Davis HM; Brown SK; Nash DW; Pennetti AM; Salzman PM; Schreiber AB; Haimovich J
Thromb Haemost; 1990 Jun; 63(3):386-91. PubMed ID: 2119524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
